EU Group Wants Greater Reciprocity As Chinese Foreign Deals Expand
Ahead of last weekend’s G20 meeting in Hangzhou, a powerful EU business group in China called for increased reciprocity over major M&A deals, suggesting that closer European scrutiny may come if China does not further open its doors. Drug price pressures in China were also flagged up as a major European concern in a new position paper.
You may also be interested in...
All eyes on a list of selected oral hepatitis C drugs that are expected to win out in China's notoriously lengthy approval battle, amid a potentially huge opening as Chinese HCV patients switch from interferon to all oral therapies.
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.
Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.